These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

116 related items for PubMed ID: 22057855

  • 1. The effect of bexarotene on atorvastatin pharmacokinetics: results from a phase I trial of bexarotene plus chemotherapy in patients with advanced non-small cell lung cancer.
    Wakelee HA, Takimoto CH, Lopez-Anaya A, Chu Q, Middleton G, Dunlop D, Ramlau R, Leighl N, Rowinsky EK, Hao D, Zatloukal P, Jacobs CD, Rodon J.
    Cancer Chemother Pharmacol; 2012 Feb; 69(2):563-71. PubMed ID: 22057855
    [Abstract] [Full Text] [Related]

  • 2. A phase I pharmacokinetic study of bexarotene with vinorelbine and cisplatin in patients with advanced non-small-cell lung cancer (NSCLC).
    Wakelee HA, Middleton G, Dunlop D, Ramlau R, Leighl N, Hao D, Lopez-Anaya A, Zatloukal P, Jacobs CD.
    Cancer Chemother Pharmacol; 2012 Mar; 69(3):815-24. PubMed ID: 22057854
    [Abstract] [Full Text] [Related]

  • 3. A phase I pharmacokinetic study of bexarotene with paclitaxel and carboplatin in patients with advanced non-small cell lung cancer (NSCLC).
    Rodon J, Jacobs CD, Chu Q, Rowinsky EK, Lopez-Anaya A, Takimoto CH, Wakelee HA.
    Cancer Chemother Pharmacol; 2012 Mar; 69(3):825-34. PubMed ID: 22057853
    [Abstract] [Full Text] [Related]

  • 4. Phase III trial comparing carboplatin, paclitaxel, and bexarotene with carboplatin and paclitaxel in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer: SPIRIT II.
    Blumenschein GR, Khuri FR, von Pawel J, Gatzemeier U, Miller WH, Jotte RM, Le Treut J, Sun SL, Zhang JK, Dziewanowska ZE, Negro-Vilar A.
    J Clin Oncol; 2008 Apr 10; 26(11):1879-85. PubMed ID: 18398153
    [Abstract] [Full Text] [Related]

  • 5. Randomized phase III trial comparing bexarotene (L1069-49)/cisplatin/vinorelbine with cisplatin/vinorelbine in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer: SPIRIT I.
    Ramlau R, Zatloukal P, Jassem J, Schwarzenberger P, Orlov SV, Gottfried M, Pereira JR, Temperley G, Negro-Vilar R, Rahal S, Zhang JK, Negro-Vilar A, Dziewanowska ZE.
    J Clin Oncol; 2008 Apr 10; 26(11):1886-92. PubMed ID: 18398154
    [Abstract] [Full Text] [Related]

  • 6. Phase II trial of bexarotene capsules in patients with advanced non-small-cell lung cancer after failure of two or more previous therapies.
    Govindan R, Crowley J, Schwartzberg L, Kennedy P, Williams C, Ekstrand B, Sandler A, Jaunakais D, Bolejack V, Ghalie R.
    J Clin Oncol; 2006 Oct 20; 24(30):4848-54. PubMed ID: 17050870
    [Abstract] [Full Text] [Related]

  • 7. Phase I and pharmacokinetic study of bexarotene in combination with gefitinib in the third-line treatment of non-small-cell lung cancer: brief report.
    Padda SK, Chhatwani L, Zhou L, Jacobs CD, Lopez-Anaya A, Wakelee HA.
    Anticancer Drugs; 2013 Aug 20; 24(7):731-5. PubMed ID: 23552470
    [Abstract] [Full Text] [Related]

  • 8. A phase I/randomized phase II, non-comparative, multicenter, open label trial of CP-547,632 in combination with paclitaxel and carboplatin or paclitaxel and carboplatin alone as first-line treatment for advanced non-small cell lung cancer (NSCLC).
    Cohen RB, Langer CJ, Simon GR, Eisenberg PD, Hainsworth JD, Madajewicz S, Cosgriff TM, Pierce K, Xu H, Liau K, Healey D.
    Cancer Chemother Pharmacol; 2007 Jun 20; 60(1):81-9. PubMed ID: 17031646
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. An open-label, crossover study of the pharmacokinetics of Insoluble Drug Delivery-MicroParticle fenofibrate in combination with atorvastatin, simvastatin, and extended-release niacin in healthy volunteers.
    Penn R, Williams RX, Guha-Ray DK, Sawyers WG, Braun SL, Rains KT.
    Clin Ther; 2006 Jan 20; 28(1):45-54. PubMed ID: 16490579
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma.
    Duvic M, Martin AG, Kim Y, Olsen E, Wood GS, Crowley CA, Yocum RC, Worldwide Bexarotene Study Group.
    Arch Dermatol; 2001 May 20; 137(5):581-93. PubMed ID: 11346336
    [Abstract] [Full Text] [Related]

  • 14. A phase I/IIA trial of continuous five-day infusion of squalamine lactate (MSI-1256F) plus carboplatin and paclitaxel in patients with advanced non-small cell lung cancer.
    Herbst RS, Hammond LA, Carbone DP, Tran HT, Holroyd KJ, Desai A, Williams JI, Bekele BN, Hait H, Allgood V, Solomon S, Schiller JH.
    Clin Cancer Res; 2003 Sep 15; 9(11):4108-15. PubMed ID: 14519633
    [Abstract] [Full Text] [Related]

  • 15. A selective retinoid X receptor agonist bexarotene (Targretin) prevents and overcomes acquired paclitaxel (Taxol) resistance in human non-small cell lung cancer.
    Yen WC, Corpuz MR, Prudente RY, Cooke TA, Bissonnette RP, Negro-Vilar A, Lamph WW.
    Clin Cancer Res; 2004 Dec 15; 10(24):8656-64. PubMed ID: 15623650
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Bexarotene and erlotinib for aerodigestive tract cancer.
    Dragnev KH, Petty WJ, Shah S, Biddle A, Desai NB, Memoli V, Rigas JR, Dmitrovsky E.
    J Clin Oncol; 2005 Dec 01; 23(34):8757-64. PubMed ID: 16314636
    [Abstract] [Full Text] [Related]

  • 19. Phase I study of biweekly paclitaxel and carboplatin for frail patients with advanced non-small cell lung cancer.
    Yanagitani N, Tsuchiya S, Kaira K, Sunaga N, Tsuchiya Y, Sato K, Watanabe S, Nomura S, Sakai S, Saito R, Mori M.
    Am J Clin Oncol; 2007 Oct 01; 30(5):487-91. PubMed ID: 17921708
    [Abstract] [Full Text] [Related]

  • 20. Paclitaxel (1-hour) and carboplatin (area under the concentration-time curve 7.5) in advanced non-small cell lung cancer: a phase II study of the Fox Chase Cancer Center and its network.
    Langer CJ, Millenson M, Rosvold E, Litwin S, McAleer CA, Bonjo CA, Ozols R.
    Semin Oncol; 1997 Aug 01; 24(4 Suppl 12):S12-81-S12-88. PubMed ID: 9331128
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.